Testosterone and hair loss: natural levels, TRT and treatment decisions

Blood testosterone cannot measure follicular sensitivity

Testosterone belongs to the androgens, hormones present in both women and men. Some is converted into dihydrotestosterone, or DHT. In susceptible scalp regions, androgen signalling contributes to miniaturisation, with follicles gradually producing finer hairs that provide less coverage. Their local response cannot be reduced to the hormone concentration measured in a blood sample.

Kische and colleagues studied 373 men from the general population in Germany. In this cross-sectional analysis, total and free testosterone concentrations were not significantly associated with hair loss or the degree of balding. Other studies have produced different findings, as the review by Tawanwongsri and colleagues explains. Taken together, the evidence does not provide a blood threshold that predicts an individual’s future baldness.

This distinction avoids two misleading assumptions: that a bald person must have high testosterone, or that a normal result excludes androgenetic alopecia. Hair coverage cannot measure sex drive or fertility. Testing requested for an endocrine concern addresses a different clinical question from examining the hair follicles themselves.

TRT is prescribed for a specific medical reason

TRT stands for testosterone replacement therapy. In a man with testosterone deficiency, its purpose is to treat the consequences of that deficiency. Tiredness alone, age or concerns about hair are insufficient reasons to decide that hormone replacement is needed. Assessment considers symptoms, blood results and the possible reasons for reduced testosterone production.

North Cumbria’s NHS endocrinology information describes confirmation through repeated morning blood measurements alongside compatible symptoms. This approach concerns the investigation of testosterone deficiency. It does not mean that everyone attending a hair appointment needs these tests, or that an online reference value can be used to select a medicine. The prescriber interprets findings in their clinical context.

Testosterone is also prescribed as part of masculinising care, with its own treatment goals and monitoring. This context needs to be distinguished from replacing deficient testosterone in a cisgender man. Studies involving one group do not automatically establish the likelihood of hair loss in another. The person’s priorities and the benefits they expect from their treatment belong in the discussion.

Using androgens to increase sporting performance or muscle size is a further, different situation. Tawanwongsri’s review highlights variation in substances, exposures and reported effects. A product advertised as a “testosterone booster” should not be equated with monitored replacement treatment. Tell your clinician which substances you actually take, including products obtained without a prescription, rather than trying to counter their effects with additional medicines.

Hair loss is possible during treatment, with no single risk estimate

North Cumbria’s NHS information lists male pattern baldness among the possible side effects of testosterone replacement. Hormone exposure can contribute to the thinning of susceptible hair. This information does not establish that everyone receiving treatment will lose hair, or allow the pace of change to be calculated from the product name.

In the retrospective cohort reported by Thoreson and colleagues, 27 of 984 people without a previous androgenetic alopecia diagnosis received that diagnosis after starting masculinising hormone therapy. The finding relied on diagnoses recorded at one centre, with limited follow-up. The authors explain that mild, unreported thinning could have been missed and that the population was relatively young.

That number describes recorded diagnoses in the cohort rather than your personal likelihood of becoming bald on TRT. It also cannot establish treatment as the sole cause in every case. Age, family history, exposure duration and the way hair loss is assessed affect study results. There is no universal point after the first few months beyond which someone can assume they will never develop thinning.

For androgen use in sport, the review published in 2025 mainly identifies small studies, users’ own reports and sometimes imprecise hair diagnoses. It also highlights the lack of evidence for medication to prevent hair loss in this setting. Presenting a combination of products as certain protection would therefore be unjustified, even when individual products have medical uses in other circumstances.

Establish the timeline before attributing a change to testosterone

The first useful reference is how the hair looked before treatment began. Earlier photographs may show that thinning was already developing, even if it attracted little attention. Record when treatment started, when the formulation or prescription changed, and when the hair concern became noticeable. This helps a clinician assess a possible relationship without mistaking a sequence of events for proof of causation.

Describe the change itself: more hair released during washing, a different hairline or gradually reduced coverage. These observations do not have identical meanings. Recent illness, weight loss or another medicine may also contribute to shedding. For example, telogen effluvium can occur alongside existing follicular miniaturisation and make the overall change more noticeable.

Report patches of hair loss, pain or scalp inflammation rather than accepting them as expected effects of testosterone. The clinician can investigate a different condition where appropriate. For broader questions involving thyroid disease, postpartum changes or signs of androgen excess, our article on hormonal hair loss addresses situations extending beyond testosterone medication alone.

Preparing this timeline also creates space to explain how the change affects you. The decision does not depend only on the area of thinning: worry, time spent checking your hair and cosmetic expectations matter too. You can ask for an assessment while remaining undecided about whether you want to start a hair treatment.

Hormone monitoring and scalp assessment answer different questions

The prescriber checks whether testosterone remains appropriate for its indication and whether it is being tolerated. A dermatologist investigates the mechanism of the hair loss and the condition of the scalp. These assessments can be coordinated. A satisfactory endocrine blood result does not exclude alopecia, while stable hair cannot establish the overall safety of hormone treatment.

TRT monitoring considers effects on red blood cells and, where relevant, the prostate and other aspects of health. The prescriber determines which investigations are needed and when. The interval between administration and blood sampling can matter when interpreting a result. Comparing values obtained under different conditions may therefore give a misleading impression of the treatment’s effect.

Hair examination assesses the distribution of thinning and features that help identify the cause. Comparable photographs may provide a record for follow-up. Further blood tests are chosen when they could answer a specific question, such as whether another contributor to shedding is present. A comprehensive panel of every hormone is not an automatic requirement whenever density appears to change.

Bring earlier results rather than arranging repeated tests independently. Explain which hair treatments you have already tried, for how long and whether they caused problems. This gives the teams a shared basis for discussing hormone follow-up, hair care or further investigation, without accumulating prescriptions whose individual purposes have not been made clear.

Discuss hair treatment with the clinician prescribing testosterone

Do not change prescribed TRT yourself because of hair loss. The decision needs to consider its benefits, the hair diagnosis and any other unwanted effects. Depending on the assessment, the clinician may discuss the hormone prescription alongside dermatological options. Switching between a gel and injections cannot be presented in advance as certain protection for the hair.

When androgenetic alopecia is confirmed, medicines directed at hair loss may be considered. Topical minoxidil and finasteride are options used for certain forms of pattern baldness, with different indications and precautions. Neither works for everyone. The NHS explains that their benefit generally depends on continuing use, so choosing one should take account of health, preferences and the practical demands of ongoing treatment.

A medicine that reduces DHT formation is not an obligatory addition to every testosterone prescription. Its expected benefit, risks and compatibility with the hormone treatment’s goals need assessment. In masculinising care in particular, this discussion should involve the team managing that treatment. A small case series or an online account cannot establish that a combination should be prescribed routinely.

Observation or cosmetic coverage can also be reasonable personal choices. Choosing either does not prevent another consultation if the situation changes. Our hair transplant guide places surgery among the available options once the diagnosis and existing medication have been clarified, rather than treating it as an automatic next step.

Finasteride requires a separate discussion of its risks

Before oral finasteride is prescribed for baldness, potential sexual and psychiatric adverse effects should be explained. These include erection or libido problems, depression and suicidal thoughts. Some adverse effects can continue after discontinuation. Describing them as invariably reversible would therefore misrepresent current safety information and could affect someone’s treatment decision.

The MHRA strengthened its safety warnings on 11 May 2026, including information about the possible relationship between sexual dysfunction and mood disorders. It advises patients to read and keep the alert card and patient leaflet supplied with finasteride. These precautions remain relevant when another clinician also prescribes testosterone; the hormonal prescription does not remove the need to discuss finasteride’s risks separately.

For people taking finasteride 1 mg for hair loss, depression or suicidal thoughts mean stopping that medicine and contacting a healthcare professional promptly, in line with MHRA advice. Immediate danger requires emergency help. Sexual difficulties should also be discussed with the prescriber. These instructions concern finasteride and do not replace the advice applicable to your testosterone treatment.

Review progress without promising regrowth after a prescription change

Follow-up should use understandable aims, such as slowing miniaturisation, retaining coverage or achieving visible improvement where possible. A photograph taken under different lighting is not enough to judge a response. Compare the same regions with similar styling and conditions, then have the changes assessed at the agreed review rather than drawing conclusions from individual pictures.

If the clinician adjusts the hormone prescription, hair will not provide an immediate measure of that decision. Established miniaturisation, another shedding cause and variable follicular responsiveness can influence what follows. Available studies cannot promise a return to the original hair coverage after reducing or stopping exposure. Medical decisions therefore need a broader perspective than the cosmetic improvement someone hopes to achieve.

Products sold as “testosterone blockers” or as protection against every hair-related effect deserve careful scrutiny. Ask for outcomes measured in comparable people using the exact product, together with an assessment of adverse effects. A change in a blood hormone value or a promotional photograph alone does not establish a lasting benefit for scalp hair.

Consider transplantation once the situation has been clarified

A transplant redistributes hair from a donor region. It does not determine whether TRT is needed or turn unexplained shedding into a surgical problem. Before discussing an operation, the team needs to understand the diagnosis, observed progression and current medicines. The native hair remaining around any grafts also needs to be considered in the longer-term plan.

Donor supply and coverage expectations limit what surgery can offer. A testosterone prescription alone neither establishes suitability nor automatically rules out an operation. Decisions about hormone treatment remain with its prescriber, working with the surgical team where necessary. No technique can promise final density or eliminate the possibility of further changes in the surrounding hair.

At Body Expert, English-speaking support and information about a hair transplant in Istanbul can help you prepare that discussion. The initial exchange clarifies the proposed project and the medical information needed for assessment. Decisions about your hair should remain consistent with the reasons your hormonal treatment was prescribed in the first place.

Sources

Kische, H., Arnold, A., Gross, S., Wallaschofski, H., Völzke, H., Nauck, M., & Haring, R. (2017). Sex hormones and hair loss in men from the general population of Northeastern Germany. JAMA Dermatology, 153(9), 935–937. https://doi.org/10.1001/jamadermatol.2017.0297

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and dutasteride: Updated safety warnings for psychiatric side effects and sexual dysfunction. MHRA safety update

NHS. (2024, January 24). Hair loss. NHS information on hair loss

North Cumbria Integrated Care NHS Foundation Trust. (2026, September 30). Testosterone replacement therapy: (TRT). Endocrinology patient information

Tawanwongsri, W., Desai, D. D., Nohria, A., Shapiro, J., & Lo Sicco, K. I. (2025). Hair loss in athletic testosterone use in males: A narrative review. International Journal of Dermatology, 64(4), 654–658. https://doi.org/10.1111/ijd.17567

Thoreson, N., Grasso, C., Potter, J., King, D. S., Peebles, J. K., & Dommasch, E. D. (2021). Incidence and factors associated with androgenetic alopecia among transgender and gender-diverse patients treated with masculinizing hormone therapy. JAMA Dermatology, 157(3), 348–349. https://doi.org/10.1001/jamadermatol.2020.5475